Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheryl Ho

Showing results (61-70 of 118) with videos related to

Pageof 12
Sort By:
Annals of Diagnostic Pathology|November 6, 2020
Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinomaJulia R Naso, Gang Wang, Norbert Banyi, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort StudyRoy Avraham Hilzenrat, Stephen Yip, Barbara Melosky, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal CarcinomaAnna Spreafico, Eric Winquist, Cheryl Ho, et al.
Current Oncology (Toronto, Ont.)|November 24, 2022
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly DosingLauren Jones, Rebekah Rittberg, Bonnie Leung, et al.
Histopathology|August 28, 2019
Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotypeJulia R Naso, Gang Wang, Alexandra Pender, et al.
Clinical Colorectal Cancer|July 31, 2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic AcidMichael Yan, Cheryl Ho, Eric Winquist, et al.
Cancer Treatment and Research Communications|December 14, 2020
Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendationsDr Andrew G Robinson, Stephanie Snow, Anthony Brade, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2009
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separationAngela M Davies, Cheryl Ho, Laurel Beckett, et al.
BMC Cancer|April 19, 2023
Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adultsBonnie Leung, Aria Shokoohi, Zamzam Al-Hashami, et al.
JCO Precision Oncology|February 21, 2025
Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial EmulationEmanuel Krebs, Deirdre Weymann, Cheryl Ho, et al.
Pageof 12

Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Annals of Diagnostic Pathology|November 6, 2020
Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinomaJulia R Naso, Gang Wang, Norbert Banyi, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort StudyRoy Avraham Hilzenrat, Stephen Yip, Barbara Melosky, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal CarcinomaAnna Spreafico, Eric Winquist, Cheryl Ho, et al.
Current Oncology (Toronto, Ont.)|November 24, 2022
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly DosingLauren Jones, Rebekah Rittberg, Bonnie Leung, et al.
Histopathology|August 28, 2019
Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotypeJulia R Naso, Gang Wang, Alexandra Pender, et al.
Clinical Colorectal Cancer|July 31, 2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic AcidMichael Yan, Cheryl Ho, Eric Winquist, et al.
Cancer Treatment and Research Communications|December 14, 2020
Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendationsDr Andrew G Robinson, Stephanie Snow, Anthony Brade, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2009
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separationAngela M Davies, Cheryl Ho, Laurel Beckett, et al.
BMC Cancer|April 19, 2023
Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adultsBonnie Leung, Aria Shokoohi, Zamzam Al-Hashami, et al.
JCO Precision Oncology|February 21, 2025
Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial EmulationEmanuel Krebs, Deirdre Weymann, Cheryl Ho, et al.
Pageof 12